Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Translate Bio
Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients.
Plus: Korea approves Celltrion antibody trial in mild patients, promising signs for Translate Bio's mRNA candidate in animal studies.
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- RaNA Therapeutics Inc.